Psoriasis is a chronic, painful, disfiguring and disabling disease which affects 125 million people (Ortonne & Prinz, 2004; Menter et al., 2008; World Health Organisation, 2016; The International Federation of Psoriasis Associations, 2017). Inflammation within the skin causes hyperproliferation of keratinocytes, and results in skin scaling and thickening, itching and erythema (Baliwag et al., 2015). Patients with psoriasis are also at an increased risk of several comorbidities, including cardiovascular and metabolic diseases, with psoriasis frequently having a profoundly negative effect on patients’ quality of life (Feldman et al, 2015; Menter et al, 2008).
Take a look through the IL-17 and psoriasis Learning Zone as we focus on the role of IL-17 family in psoriasis pathophysiology and review how disease severity is assessed and how modern biologics allow us to aim higher and target complete skin clearance. Also, explore the key clinical trial data for anti-IL-17 biologics in psoriasis and find out what the experts think of them.
IL-17 plays a central role in the psoriatic inflammatory process. Discover the mechanism of action of the different biologics targeting the IL-17 pathway.
We need to aim higher when treating patients with psoriasis. Achieving PASI 100 is key to improving patient quality of life.